The first conformation-specific immunotherapy efficacy study for ALS involved passive immunization of SOD1G93A mice with misfolded SOD1-specific monoclonal antibodies or their binding fragments [230]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.